

Sveinbjorn Gizurarson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1353014/publications.pdf>

Version: 2024-02-01

57
papers

1,914
citations

279798

23
h-index

265206

42
g-index

58
all docs

58
docs citations

58
times ranked

2181
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of trehalose, antioxidants, and acetate buffer concentration on oxytocin stability. Journal of Peptide Science, 2021, 27, e3324.	1.4	1
2	Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics, 2021, 13, 501.	4.5	15
3	Effect of Doxycycline Microencapsulation on Buccal Films: Stability, Mucoadhesion and In Vitro Drug Release. Gels, 2021, 7, 51.	4.5	4
4	Endothelium-Derived Hyperpolarizing Factor (EDHF) Mediates Acetylsalicylic Acid (Aspirin) Vasodilation of Pregnant Rat Mesenteric Arteries. International Journal of Molecular Sciences, 2021, 22, 10162.	4.1	2
5	Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Scandinavian Journal of Gastroenterology, 2021, 56, 128-136.	1.5	5
6	Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews, 2020, 296, 169-190.	6.0	56
7	Galectin 13 (PP13) Facilitates Remodeling and Structural Stabilization of Maternal Vessels during Pregnancy. International Journal of Molecular Sciences, 2019, 20, 3192.	4.1	36
8	<p>Stability of thromboxane in blood samples</p>. Vascular Health and Risk Management, 2019, Volume 15, 143-147.	2.3	5
9	<p>Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration</p>. International Journal of Women's Health, 2019, Volume 11, 213-222.	2.6	12
10	Aspirin causes endothelium-dependent vasodilation of resistance arteries from non-gravid and gravid rats. Pregnancy Hypertension, 2019, 15, 141-145.	1.4	9
11	Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Research Bulletin, 2018, 143, 155-170.	3.0	468
12	Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits. Drug Design, Development and Therapy, 2018, Volume 12, 1977-1983.	4.3	5
13	Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. European Journal of Pharmaceutical Sciences, 2017, 102, 46-54.	4.0	24
14	Placental protein 13 (PP13)-induced vasodilation of resistance arteries from pregnant and nonpregnant rats occurs via endothelial-signaling pathways. Hypertension in Pregnancy, 2017, 36, 186-195.	1.1	26
15	The Role of the Carbohydrate Recognition Domain of Placental Protein 13 (PP13) in Pregnancy Evaluated with Recombinant PP13 and the DelT221 PP13 Variant. PLoS ONE, 2014, 9, e102832.	2.5	19
16	Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy. Frontiers in Immunology, 2014, 5, 348.	4.8	90
17	Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting Î² ₂ -agonists in obstructive lung diseases: a population-based, observational study. International Journal of Clinical Practice, 2014, 68, 812-819.	1.7	17
18	InÂvitro evaluation of pulmonary deposition of airborne volcanic ash. Atmospheric Environment, 2013, 70, 18-27.	4.1	22

#	ARTICLE	IF	CITATIONS
19	Effects of Placental Protein 13 on the Cardiovascular System in Gravid and Non-Gravid Rodents. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 257-264.	1.4	32
20	Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. <i>International Journal of Clinical Practice</i> , 2013, 67, 904-910.	1.7	28
21	Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. <i>Human Reproduction Update</i> , 2013, 19, 391-405.	10.8	63
22	Serum leptin concentrations, leptin mRNA expression, and food intake during the estrous cycle in rats. <i>Laboratory Animal Research</i> , 2013, 29, 1.	2.5	14
23	Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. <i>Scandinavian Journal of Public Health</i> , 2012, 40, 663-667.	2.3	6
24	Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery. <i>Current Drug Delivery</i> , 2012, 9, 566-582.	1.6	166
25	Single- and Repeated-dose Local Toxicity in the Nasal Cavity of Rabbits after Intranasal Administration of Different Glycols for Formulations Containing Benzodiazepines. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 377-383.	2.4	18
26	Immunization prevents DDT buildup in mouse tissues. <i>International Immunopharmacology</i> , 2007, 7, 1179-1184.	3.8	5
27	Mucosal Tolerance to KLH Reduces BSA-Induced Arthritis in Rats—An Indication of Bystander Suppression. <i>Journal of Clinical Immunology</i> , 2007, 27, 284-293.	3.8	5
28	Induction of Protective and Specific Antibodies against Cocaine by Intranasal Immunisation Using a Glyceride Adjuvant. <i>Biological and Pharmaceutical Bulletin</i> , 2005, 28, 1038-1042.	1.4	18
29	Intranasal bioavailability of diazepam in sheep correlated to rabbit and man. <i>International Journal of Pharmaceutics</i> , 2002, 231, 67-72.	5.2	18
30	Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 521-527.	2.4	32
31	Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies. <i>Antiviral Research</i> , 2001, 52, 43-53.	4.1	34
32	Intranasal absorption of buprenorphine—in vivo bioavailability study in sheep. <i>International Journal of Pharmaceutics</i> , 2000, 205, 159-163.	5.2	27
33	Intranasal Administration of Diazepam Aiming at the Treatment of Acute Seizures: Clinical Trials in Healthy Volunteers.. <i>Biological and Pharmaceutical Bulletin</i> , 1999, 22, 425-427.	1.4	32
34	Intranasal Immunization with Pneumococcal Polysaccharide Conjugate Vaccines Protects Mice against Invasive Pneumococcal Infections. <i>Infection and Immunity</i> , 1999, 67, 4128-4133.	2.2	46
35	Selective Augmentation of Antibodies in Various Mucosal Regions, after Intranasal Immunization with Diphtheria in Mice. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1267-1269.	3.3	3
36	Intranasal Vaccination: Pharmaceutical Evaluation of the Vaccine Delivery System and Immunokinetic Characteristics of the Immune Responses. <i>Pharmaceutical Development and Technology</i> , 1998, 3, 385-394.	2.4	7

#	ARTICLE	IF	CITATIONS
37	Clinically Relevant Vaccine-Vaccine Interactions. <i>BioDrugs</i> , 1998, 9, 443-453.	4.6	7
38	Solubilization of Various Benzodiazepines for Intranasal Administration, a Pilot Study. <i>Pharmaceutical Development and Technology</i> , 1997, 2, 293-296.	2.4	9
39	Olfactory Absorption of Insulin to the Brain. <i>Drug Delivery</i> , 1997, 4, 195-200.	5.7	25
40	Intranasal booster vaccination against diphtheria and tetanus in man. <i>Vaccine</i> , 1997, 15, 307-316.	3.8	51
41	Optimal Delivery of Vaccines. <i>Clinical Pharmacokinetics</i> , 1996, 30, 1-15.	3.5	10
42	Intranasal administration of insulin to rabbits using glycofurol as an absorption promoter. <i>International Journal of Pharmaceutics</i> , 1996, 128, 287-289.	5.2	23
43	Selective delivery of insulin into the brain: Intraolfactory absorption. <i>International Journal of Pharmaceutics</i> , 1996, 140, 77-83.	5.2	14
44	Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs. <i>Toxicology</i> , 1996, 107, 61-68.	4.2	13
45	Intranasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. <i>Vaccine</i> , 1995, 13, 617-621.	3.8	19
46	Insulin and didecanoyl-L- α -phosphatidylcholine: in vitro study of the transport through rabbit nasal mucosal tissue. <i>International Journal of Pharmaceutics</i> , 1993, 89, 147-153.	5.2	21
47	The relevance of nasal physiology to the design of drug absorption studies. <i>Advanced Drug Delivery Reviews</i> , 1993, 11, 329-347.	13.7	87
48	Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. <i>Vaccine</i> , 1992, 10, 101-106.	3.8	60
49	The viability of isolated rabbit nasal mucosa in the Ussing chamber, and the permeability of insulin across the membrane. <i>International Journal of Pharmaceutics</i> , 1992, 87, 125-132.	5.2	33
50	Intranasal administration of insulin to humans. <i>Diabetes Research and Clinical Practice</i> , 1991, 12, 71-84.	2.8	47
51	The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. <i>Vaccine</i> , 1991, 9, 825-832.	3.8	41
52	Estimating tissue permeability and other bioelectrical parameters using membrane voltage and short-circuit current. <i>Chemical and Pharmaceutical Bulletin</i> , 1991, 39, 1636-1637.	1.3	4
53	Study of Nasal Enzyme Activity towards Insulin. In Vitro. <i>Chemical and Pharmaceutical Bulletin</i> , 1991, 39, 2155-2157.	1.3	27
54	Pharmacokinetics of Intranasal Drug Administration: The Influence of Some Biological Factors. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 505-506.	3.3	5

#	ARTICLE	IF	CITATIONS
55	The influence of insulin and some excipients used in nasal insulin preparations on mucociliary clearance. <i>International Journal of Pharmaceutics</i> , 1990, 65, 243-247.	5.2	45
56	A simple flow-injection method for the determination of blood glucose using a Technicon immobilized enzyme coil. <i>Journal of Automated Methods and Management in Chemistry</i> , 1989, 11, 87-88.	0.3	1
57	Activated carbon for the removal of the ointment base before kinetic assay of nitroglycerin ointment. <i>Fresenius Zeitschrift für Analytische Chemie</i> , 1988, 332, 177-178.	0.8	2